RT Journal Article
T1 Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies.
A1 Izquierdo, Guillermo
A1 García-Agua Soler, Nuria
A1 Rus, Macarena
A1 García-Ruiz, Antonio José
K1 Clinical practice
K1 Effectiveness
K1 Glatiramer acetate
K1 Multiple sclerosis
K1 Therapy
K1 Treatment
K1 Enfermedad crónica
K1 Oportunidad relativa
K1 Calidad de vida
K1 Recurrencia
AB OBJECTIVETo assess the effectiveness of glatiramer acetate (GA) compared to other multiple sclerosis (MS) therapies in routine clinical practice.MATERIALS AND METHODSObservational cohort study carried out in MS patients treated with GA (GA cohort) or other MS therapies -switched from GA- (non-GA cohort). Study data were obtained through review of our MS patient database. The primary endpoint was the Expanded Disability Status Scale (EDSS) scores reached at the end of treatment/last check-up.RESULTSA total of 180 patients were included: GA cohort n = 120, non-GA cohort n = 60. Patients in the GA cohort showed better EDSS scores at the end of treatment/last check-up (mean ± SD, 2.8 ± 1.8 vs. 3.9 ± 2.2; P = 0.001) and were 1.65 times more likely to show better EDSS scores compared to the non-GA cohort (odds ratio, 0.606; 95%CI, 0.436-0.843; P = 0.003). Patients in the GA cohort showed longer mean time to reach EDSS scores of 6 (209.1 [95%CI, 187.6-230.6] vs. 164.3 [95% CI, 137.0-191.6] months; P = 0.004) and slower disability progression (hazard ratio, 0.415 [95%CI, 0.286-0.603]; P < 0.001). The annualized relapse rate was lower in the GA cohort (mean ± SD, 0.5 ± 0.5 vs. 0.8 ± 0.5; P = 0.001) and patients' quality of life was improved in this study cohort compared to the non-GA cohort (mean ± SD, 0.7 ± 0.1 vs. 0.6 ± 0.2; P = 0.01).CONCLUSIONSGA may slow down the progression of EDSS scores to a greater extent than other MS therapies, as well as achieving a greater reduction in relapses and a greater improvement in patients' quality of life. Switching from GA to other MS therapies has not proved to entail a better response to treatment.
PB Wiley Open Access
YR 2015
FD 2015-06
LK http://hdl.handle.net/10668/2106
UL http://hdl.handle.net/10668/2106
LA en
NO Izquierdo G, García-Agua Soler N, Rus M, García-Ruiz AJ. Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies. Brain Behav. 2015; 5(6):e00337
NO Journal Article; Research Support, Non-U.S. Gov't;
DS RISalud
RD Apr 8, 2025